Peptide Patent Wars: Novo Nordisk, Eli Lilly, and the Fight Over GLP-1 Compounding

Few legal battles in the pharmaceutical industry have drawn as much public attention as the ongoing fight between major drug manufacturers and compounding pharmacies over GLP-1 receptor agonist peptides. At the center of this conflict are two of the world's most valuable drugs — semaglutide (Ozempic/Wegovy) made by Novo Nordisk, and tirzepatide (Mounjaro/Zepbound) made by Eli Lilly — and the compounding pharmacies that began producing lower-cost versions during federal drug shortage declarations.

The stakes are enormous. The GLP-1 market is projected to exceed $100 billion globally by 2030. For Novo Nordisk and Eli Lilly, compounded versions represent both a revenue threat and a patent challenge. For compounding pharmacies and their patients, these cases will determine whether affordable alternatives to brand-name peptide drugs can legally exist.

How GLP-1 Compounding Became Legal — and Controversial

Under normal circumstances, compounding pharmacies cannot produce copies of commercially available, FDA-approved drugs. However, the Federal Food, Drug, and Cosmetic Act contains an exception: when the FDA places a drug on its Drug Shortage List, compounding pharmacies operating under sections 503A and 503B may compound that drug to help address the shortage.

Beginning in 2022, both semaglutide and tirzepatide were placed on the FDA's drug shortage list due to unprecedented demand driven by their use for weight management. This triggered a wave of compounding pharmacy activity, with hundreds of 503A and 503B facilities across the country producing compounded versions of these peptides — often at a fraction of the brand-name price.

Novo Nordisk and Eli Lilly pushed back aggressively, arguing that compounders were exploiting the shortage provision, producing substandard products, and infringing on their patents and regulatory exclusivities.

The Patent Landscape

Both semaglutide and tirzepatide are protected by extensive patent portfolios. Understanding the patent landscape is essential to grasping the legal arguments on both sides.

Drug	Manufacturer	Key Patents	Patent Expiration	Brands
Semaglutide	Novo Nordisk	Compound, formulation, method-of-use patents	2032-2037 (varies by patent)	Ozempic, Wegovy, Rybelsus
Tirzepatide	Eli Lilly	Compound, formulation, dual-agonist mechanism patents	2036-2040 (varies by patent)	Mounjaro, Zepbound

Manufacturers argue that compounding pharmacies are infringing these patents by producing the same active pharmaceutical ingredient. Compounders counter that section 503A and 503B of the FD&C Act provide a statutory right to compound during shortages, and that this right is not overridden by patent protections.

This legal question — whether compounding rights under federal pharmacy law supersede patent exclusivity — has not been definitively resolved by the courts, making the ongoing litigation all the more significant.

Timeline of Major Legal Actions

The legal battles have escalated rapidly over the past two years:

Late 2023: Novo Nordisk sends cease-and-desist letters to dozens of compounding pharmacies producing semaglutide, asserting patent infringement and product quality concerns
Early 2024: Eli Lilly files its first federal lawsuits against compounding pharmacies and associated med spas marketing compounded tirzepatide
Mid 2024: Novo Nordisk files suit against multiple 503B outsourcing facilities, alleging trademark infringement (use of "semaglutide" name) and patent infringement
Late 2024: The Outsourcing Facilities Association (OFA) and other trade groups file legal challenges seeking to prevent the FDA from removing semaglutide from the shortage list
Early 2025: FDA announces semaglutide shortage has been resolved for certain dosage forms, triggering a 60-day wind-down period for compounders
Mid 2025: Multiple compounding pharmacies file emergency motions to continue compounding, arguing the shortage resolution was premature
Late 2025: Federal courts issue mixed rulings — some granting temporary restraining orders allowing compounding to continue, others siding with manufacturers
Early 2026: Appeals consolidate in multiple circuit courts; industry awaits definitive appellate rulings on the intersection of compounding rights and patent law

The Drug Shortage Question

Central to the entire dispute is the FDA's Drug Shortage List. As long as semaglutide or tirzepatide appears on this list, compounding pharmacies have a clear statutory basis for producing these peptides. The moment a drug is removed from the list, that legal foundation narrows dramatically.

Novo Nordisk and Eli Lilly have both invested heavily in manufacturing capacity to resolve the shortages, in part because doing so eliminates the compounding exception. Both companies have announced multi-billion-dollar manufacturing expansions specifically to ensure supply meets demand.

However, compounding pharmacy advocates argue that "shortage resolution" should account for practical access, not just theoretical supply. Even if manufacturers produce enough units, many patients cannot afford the brand-name pricing — which can exceed $1,000 per month without insurance — and insurance coverage for weight management indications remains inconsistent.

Patent Law vs. Compounding Rights: The Core Legal Question

The most consequential legal question in these cases is whether federal compounding statutes (503A/503B) create an implicit exception to patent law. This is largely uncharted territory.

Manufacturers' argument: Patent rights under Title 35 of the U.S. Code are absolute. No provision of the FD&C Act explicitly exempts compounding pharmacies from patent infringement liability. The drug shortage exception allows compounding from a regulatory perspective (FDA will not take enforcement action) but does not shield compounders from patent claims brought by the patent holder in federal court.

Compounders' argument: The FD&C Act, as amended by the DQSA, creates an affirmative right to compound during drug shortages. If Congress intended compounding to be available during shortages, it would be illogical for patent law to simultaneously block that very compounding. Additionally, compounders argue that their products are not identical to the branded products and may use different salt forms, concentrations, or delivery methods.

Legal scholars remain divided. Some predict that appellate courts will side with manufacturers on the patent question while acknowledging the FDA's authority to exercise enforcement discretion on the regulatory side. Others anticipate that courts will find an implied compounding exception, particularly where public health (drug shortages) is at stake.

Impact on Patient Access and Pricing

The practical consequences of these legal battles are felt most directly by patients. During the period when compounding was widely available, patients reported accessing semaglutide for $150-400 per month — compared to $800-1,350 for brand-name Wegovy or Ozempic without insurance. For many patients, particularly those whose insurance does not cover GLP-1 drugs for weight management, compounded versions were the only affordable option.

If courts ultimately side with manufacturers and restrict compounding, patient access could be severely constrained. Industry observers have noted that this outcome would likely intensify pressure on Congress to address GLP-1 drug pricing through legislation, and on the Centers for Medicare & Medicaid Services (CMS) to expand coverage criteria.

What Happens Next

Several key developments are expected in 2026:

Circuit court rulings: Appellate decisions on the patent-vs-compounding question could establish binding precedent in multiple jurisdictions
FDA shortage list updates: Ongoing monitoring of supply and demand will determine whether tirzepatide and remaining semaglutide formulations stay on the shortage list
Congressional action: Multiple bills addressing compounding rights and GLP-1 pricing have been introduced; hearings are expected throughout 2026
State-level initiatives: Several states are exploring legislation to protect patient access to compounded medications regardless of federal patent disputes

FAQ: GLP-1 Patent and Compounding Disputes

Can I still get compounded semaglutide?

Availability depends on the current FDA shortage status and your state's laws. As of early 2026, some compounding pharmacies continue to produce semaglutide under ongoing litigation and temporary court orders. However, the legal landscape is changing rapidly. Check the FDA's drug shortage database and consult with a licensed healthcare provider for current availability in your area.

Are compounded GLP-1 peptides safe?

The FDA has raised concerns about the quality and sterility of some compounded GLP-1 products. Compounded medications are not subject to the same premarket testing as FDA-approved drugs. However, 503B outsourcing facilities are subject to FDA inspection and must follow current good manufacturing practices (cGMP). Quality varies by pharmacy — patients should verify that their compounder is a registered 503B facility with a clean FDA inspection history.

Could Congress intervene in these lawsuits?

Congress has the authority to amend patent law or compounding statutes to clarify the relationship between the two. Several proposed bills would explicitly protect compounding during drug shortages or create new pathways for affordable access to peptide-based medications. However, pharmaceutical industry lobbying is significant, and legislative timelines are uncertain.

What is the difference between compounded semaglutide and brand-name Wegovy?

Brand-name Wegovy (and Ozempic) is manufactured by Novo Nordisk under FDA approval, with established quality controls, specific formulations, and fixed dosing in pre-filled injection pens. Compounded semaglutide uses the same active ingredient but may differ in formulation (often provided in multi-dose vials rather than pens), concentration, and inactive ingredients. The active peptide is the same molecule, but the final product is not FDA-approved and has not undergone the same clinical trials as the brand-name version.

Sources and References

This article is for educational and informational purposes only and does not constitute legal, financial, or medical advice. The legal landscape described in this article is actively evolving. Consult qualified legal and healthcare professionals for guidance specific to your situation.